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Mononuclear cells and vascular
repair in HHT
Calinda K. E. Dingenouts , Marie-José Goumans* and Wineke Bakker *
Department of Molecular Cell Biology, Leiden University Medical Center, Leiden, Netherlands
Hereditary hemorrhagic telangiectasia (HHT) or Rendu–Osler–Weber disease is a rare
genetic vascular disorder known for its endothelial dysplasia causing arteriovenous
malformations and severe bleedings. HHT-1 and HHT-2 are the most prevalent variants
and are caused by heterozygous mutations in endoglin and activin receptor-like kinase
1, respectively. An undervalued aspect of the disease is that HHT patients experience
persistent inflammation. Although endothelial and mural cells have been the main
research focus trying to unravel the mechanism behind the disease, wound healing is a
process with a delicate balance between inflammatory and vascular cells. Inflammatory
cells are part of the mononuclear cells (MNCs) fraction, and can, next to eliciting an
immune response, also have angiogenic potential. This biphasic effect of MNC can
hold a promising mechanism to further elucidate treatment strategies for HHT patients.
Before MNC are able to contribute to repair, they need to home to and retain in ischemic
and damaged tissue. Directed migration (homing) of MNCs following tissue damage is
regulated by the stromal cell derived factor 1 (SDF1). MNCs that express the C-X-C
chemokine receptor 4 (CXCR4) migrate toward the tightly regulated gradient of SDF1.
This directed migration of monocytes and lymphocytes can be inhibited by dipeptidyl
peptidase 4 (DPP4). Interestingly, MNC of HHT patients express elevated levels of
DPP4 and show impaired homing toward damaged tissue. Impaired homing capacity
of the MNCs might therefore contribute to the impaired angiogenesis and tissue repair
observed in HHT patients. This review summarizes recent studies regarding the role of
MNCs in the etiology of HHT and vascular repair, and evaluates the efficacy of DPP4
inhibition in tissue integrity and repair.
Keywords: homing, myocardial ischemia and infarction, TGF-beta, dipeptidyl peptidase 4, mononuclear cells,
regenerative medicine, tissue therapy, cardiovascular disease
HHT and the Underlying Genetic Causes
Hereditary hemorrhagic telangiectasia (HHT) or Rendu–Osler–Weber disease is a genetic vascular
disorder. The onset of the disease and severity is variable for each individual patient and will inten-
sify as the disease progresses with age (Plauchu et al., 1989). To be diagnosed with HHT, a patient
has to have 3 of the 4 Curaçao criteria, namely epistaxis, telangiectasias, arteriovenous malforma-
tions (AVMs), or a ﬁrst degree relative with HHT. After diagnosis, patients are genetic screened
to identify the underlying mutation (Shovlin et al., 2000). Since the underlying mutation cannot
always be identiﬁed in every patient, the clinical symptoms are still important for the diagnosis of
HHT. To date, four genes were found to be mutated, resulting in four diﬀerent HHT subtypes. All
genes identiﬁed are components of the transforming growth factor beta (TGFβ) signaling pathway.
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The identiﬁed mutations will not generate aberrant proteins, but
will rather result in haploinsuﬃciency, a reduction of the func-
tional protein levels by 50%, causing a disbalance in the TGFβ
signaling pathway (Bourdeau et al., 2000; Abdalla and Letarte,
2006). HHT-1 is the most prevalent HHT subtype, comprising
53% of Dutch HHT patients (Letteboer et al., 2008). The HHT-
1 mutation lies in the endoglin gene (McAllister et al., 1994), a
TGFβ co-receptor modulating TGFβ and BMP signaling and cru-
cial for angiogenesis and vascular repair (Pardali et al., 2010). The
second most prevalent gene found to be mutated is the activin
receptor-like kinase 1 (ALK1) and causes HHT-2 (Johnson et al.,
1996). Approximately 40% of the Dutch HHT patients have this
HHT-2 variant (Letteboer et al., 2008). ALK1 is a type I recep-
tor able to signal downstream of either BMP or TGFβ, depending
on the ligand availability and receptor context (Goumans et al.,
2009). Hundreds of variants have been described for both HHT-1
and HHT-2, amounting to ∼87% of HHT cases globally, leaving
about 15–20% of HHT families without a characterized mutation
(Garg et al., 2014). HHT-3 and HHT-4 are linked to loci on chro-
mosomes 5 and 7 respectively, but the exact genes aﬀected are not
yet identiﬁed (Cole et al., 2005; Bayrak-toydemir et al., 2006). The
third and fourth gene in which mutations are found causing HHT
are BMP9 and SMAD4. Interestingly, BMP9 is a ligand for ALK1
(Wooderchak-Donahue et al., 2013) and SMAD4 is a transcrip-
tion factor involved in transducing BMP and TGFβ signals from
the cell membrane into the nucleus. Mutations in SMAD4 cause
a combined syndrome of HHT and juvenile polyposis (Gallione
et al., 2006).
In this review the consequences of a disturbed TGFβ signal-
ing cascade caused by the diﬀerent mutations found in HHT will
be described, especially how this aﬀects mononuclear cell (MNC)
functioning and their capacity to repair.
Impaired Angiogenesis in HHT is
Caused by Disrupted TGFβ Signaling
As mentioned above, all genes that have been found mutated in
HHT are linked to TGFβ signaling. Upon tissue damage, TGFβ
is released by the extracellular matrix, apoptotic cells or secreted
by platelets, macrophages and T lymphocytes (Grainger et al.,
2000; Wan et al., 2012). TGFβ is the prototypic member of a large
superfamily to which also activin and BMPs belong. To be able
to signal, TGFβ ligands bind to the TGFβ receptor type II, and
BMP ligands can to bind to both the BMP receptor types I and
II (Goumans et al., 2009). Upon binding of the ligand, a TGFβ
type I receptor is recruited and a heterotetrameric complex is
formed, which in turn phosphorylates intracellular receptor regu-
lated SMAD proteins. In endothelial cells, TGFβ can signal using
two type I receptors, namely via ALK5 resulting in the phos-
phorylation of SMAD 2 and 3, or by the BMP type I receptor,
ALK1 followed by activation of SMAD 1 and 5. ALK1 can only
form a complex with the TGFβ receptor type II in the presence of
ALK5 in the tetrameric complex and the presence of endoglin as
co-receptor (Lebrin et al., 2004; Goumans et al., 2009).
The presence of these two pathways might explain the
biphasic eﬀect TGFβ has on angiogenesis, since TGFβ-ALK1
signaling induces endothelial cell proliferation and migration,
whereas TGFβ-ALK5 signaling leads to a quiescent endothe-
lium. Endoglin mainly stimulates the TGFβ-ALK1 pathway, and
is thought to suppress TGFβ-ALK5 signaling (Goumans et al.,
2008). After phosphorylation, the receptor regulated SMADs
form a complex with SMAD4, and translocate into the nucleus
where they act as a transcription factor to ensure target gene
expression.
Since endoglin is involved in endothelial cell proliferation,
migration, and remodeling of the extracellular matrix (Lebrin
et al., 2004; Abdalla and Letarte, 2006), the vascular defects
and impaired angiogenesis observed in HHT-1 are largely
explained by malfunctioning of the endothelial cells (Jerkic et al.,
2006; Düwel et al., 2007; Liu et al., 2014). However, although
highly expressed on activated endothelial cells, endoglin is also
present on stromal cells, smooth muscle cells, mesenchymal
and hematopoietic stem cells, and MNC (Kapur et al., 2013).
The importance of endoglin for endothelial cell homeostasis
became evident when endothelial cells that lack one allele of
endoglin were studied. Endoglin heterozygous endothelial cells
exhibit reduced ALK1-Smad1/5 signaling. Unexpectedly, these
cells adapted their ALK5 expression with a decrease of 80% and
therefore also have reduced ALK5-Smad2/3 signaling (Lebrin
et al., 2004; Lebrin and Mummery, 2008). In contrast, endoglin
deﬁcient endothelial cells show an increased ALK1 and ALK5
signaling (Pece-Barbara et al., 2005). This demonstrates that
endoglin haploinsuﬃciency aﬀects downstream TGFβ signal-
ing and gene adaptation. When comparing diﬀerent studies, we
could conclude that the mutations underlying the various HHT
subtypes converge in the ALK1 arm of the TGFβ pathway; aﬀect-
ing endoglin, ALK1, BMP9, and SMAD4 proteins. The imbal-
ance caused by the haploinsuﬃciency of these proteins skews
TGFβ signaling toward endothelial cell quiescent state, leading
to impaired angiogenesis after tissue injury.
Another manifestation in HHT is the formation of weak blood
vessels, as a result of impaired maturation. Lebrin et al. (2010)
found that the anti-angiogenic drug thalidomide induces the
recruitment of mural cells such as pericytes and vascular smooth
muscle cells. The recruitment of these cells to vessel branching
points enhanced the maturation of HHT vessels and reduced
the occurrence of epistaxis (Lebrin et al., 2010). Unfortunately
thalidomide treatment is prone to side eﬀects such as periph-
eral neuropathy and fatigue (Ghobrial and Rajkumar, 2003;
Morawska and Grzasko, 2014). Current research is focused on
ﬁnding a compound with similar mode of action, restoring the
maturation of the diseased blood vessels.
Unraveling the Etiology and
Mechanism Behind HHT: Lessons from
Mouse Models
Murine models have given valuable insights into the mecha-
nism behind the mutations found in HHT patients. The dif-
ferent heterozygous mouse models conﬁrmed that the defect
in TGFβ signaling due to the haploinsuﬃciency resembled
HHT, as they developed similar vascular abnormalities like
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telangiectasias, AVMs and endothelial dysplasia (Lowery and de
Caestecker, 2010). While endoglin deﬁcient mice are embryon-
ically lethal around embryonic day (E)10.5 and show defects
in cardiac development and impaired maturation of blood ves-
sels in the yolk sac (Bourdeau et al., 1999; Arthur et al.,
2000), endoglin heterozygous mice are vital. However, adult
endoglin heterozygous mice show impaired angiogenesis, AVMs
and display cerebral vascular abnormalities (Satomi et al.,
2003; van Laake et al., 2006). Choi et al. (2014) speciﬁcally
deleted endoglin in endothelial and smooth muscle cells using
the SM22α-Cre mouse model. Combined with local VEGF
stimulation in the brain, this endoglin deletion causes cere-
bral AVMs (Choi et al., 2014). However, VEGF stimulation
together with deletion of endoglin in the endothelium alone
is already enough to cause vascular dysplasia (Choi et al.,
2012).
Activin receptor-like kinase 1 deﬁcient mice are also embryon-
ically lethal on E10.5 due to severe hematopoietic defects, AVMs
and impaired angiogenesis in the embryo as well as in the yolk sac
(Oh et al., 2000; Urness et al., 2000; Sorensen et al., 2003). ALK1
heterozygous mice are viable and display HHT-2 like symp-
toms, such as vascular malformations, lesions, and hemorrhages
(Srinivasan et al., 2003). Interestingly, endothelial cell speciﬁc
ALK1 deletion leads to the formation of retinal AVMs and pul-
monary hemorrhages, but also causes a reduced expression of
endoglin (Tual-Chalot et al., 2014).
Since SMAD4 null mice are embryonically lethal at day 7, and
SMAD4 heterozygous mice show no abnormalities, developing a
mouse model for this subtype of HHT is not possible (Takaku
et al., 1998). Even an endothelium speciﬁc SMAD4 deletion is
embryonically lethal, as it shows angiogenic as well as cardiac
defects (Lan et al., 2007; Qi et al., 2007).
The most recent HHTmutation identiﬁed lies within the gene
for BMP9. Surprisingly, BMP9 knock-out mice develop normally
and do not show any vascular defects (Chen et al., 2013). This lack
of phenotype is most likely due to rescue by the closely related
BMP10. Interestingly, injection of BMP10 neutralizing antibody
into the BMP9 knock-out mice reduced the expansion of the reti-
nal vasculature (Ricard et al., 2012; Chen et al., 2013). This shows
that removal of both BMP9 and BMP10 ligands is necessary to
induce vascular abnormalities.
In conclusion, mice heterozygous for endoglin or endothelium
speciﬁc deletion of endoglin resembling HHT-1 (Arthur et al.,
2000; Choi et al., 2012, 2014) and animals heterozygous for ALK1
mice resembling HHT-2 (Srinivasan et al., 2003), are suitable
mouse models to unravel the etiology and mechanism behind
HHT. Whether or not the double knock-out for BMP9/BMP10
will resemble a HHT subtype still needs to be established.
Endoglin Expression on MNC and its
Implications for Inflammatory and
Regenerative Properties
As mentioned, endoglin and ALK1 are not only expressed on
endothelial cells, but also on some subsets of the MNC frac-
tion. The MNC fraction is an essential cell population during the
inﬂammatory response and the repair process of damaged tissue.
The MNC fraction consists of numerous diﬀerent cell types with
highly adaptive responses and cell plasticity. The most predom-
inant cell types within the MNC fraction are T lymphocytes,
monocytes, and macrophages. Furthermore, there are several
smaller cell populations present, such as natural killer cells, den-
dritic cells and endothelial progenitor cells (EPCs; Isner et al.,
2001).
In healthy subjects, endoglin is upregulated in activated
monocytes, but this is impaired in HHT-1 patients (Sanz-
Rodriguez et al., 2004). Interestingly, the increased expression of
endoglin on activated monocytes was also impaired in HHT-2
patients (Sanz-Rodriguez et al., 2004). We propose that impaired
signaling via endoglin and subsequent ALK1 signaling in MNC,
and especially monocytes, might be causing immunological prob-
lems such as increased infection rate and leukopenia as reported
(Guilhem et al., 2013; Peter et al., 2014).
Two Phases of MNC Recruitment during
Tissue Repair
During tissue repair, two phases are essential, the inﬂammation
and the regeneration phase. The MNC, and especially the mono-
cytes and macrophages, play important and distinct roles in these
two phases (Figure 1).
The ﬁrst inﬂammatory phase is known as the acute phase,
characterized by the inﬁltration of neutrophils, T lympho-
cytes and activated monocytes diﬀerentiating into inﬂamma-
tory macrophages (Figure 1). T lymphocytes and inﬂammatory
macrophages are necessary for the clearance of any infectious
organisms and the removal of dead tissue and cell debris after an
ischemic event and/or injury. The second regenerative phase is
initiated when the initial inﬂux of inﬂammatory cells is (partly)
cleared from the site of injury. Secreted cytokines and growth
factors stimulate a secondary phase of MNC and resident cells
toward the regeneration area. Locally, TGFβ levels are ele-
vated which will activate local endothelial cells and stimulate
proliferation and repair/replace damaged vessels. Furthermore,
the remaining MNCs, including a second type of monocytes
FIGURE 1 | Two phases of MNC recruitment. In the acute phase (day 1–4)
of tissue injury acute inflammation is initiated by the recruitment of neutrophils,
monocytes and inflammatory type macrophages.Resolution of the
inflammatory response in regeneration phase is elicited by the
recruitment/dedifferentiation of regenerative monocytes/macrophages and
lymphocytes. Mϕ, macrophages. Adapted from Nahrendorf et al. (2007) and
Loebbermann et al. (2012).
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that diﬀerentiate toward regenerative macrophages, are recruited
which will shift the microenvironment toward tissue repair.
The regenerative macrophages are able to induce cell prolif-
eration, angiogenesis, and tissue remodeling. For an optimal
resolution and recovery of damage tissues, both the inﬂamma-
tory as well as regenerative macrophages are essential players.
To note, macrophages have a high plasticity and are able to
change between phenotypes, depending on their microenviron-
ment (Kim and Hematti, 2010; Sindrilaru et al., 2011; Mantovani
et al., 2013). Furthermore, macrophages have the capacity to
interact with lymphocytes, as well as interact with and inﬂu-
ence the viability and growth of mesenchymal stem cells and
progenitor cells (Freytes et al., 2012). In addition, recent studies
demonstrated that TGFβ stimulates the proliferation of regener-
ative macrophages, inducing a pro-ﬁbrotic phenotype (Murray
et al., 2011).
MNC and Inflammation in HHT
The composition of the MNC fraction is diﬀerent in HHT
patients compared to healthy subjects. The amount of periph-
eral blood NK and T lymphocytes was found to be reduced in
HHT-1, HHT-2, but also in the unidentiﬁed subtypes of HHT
patients, while the B lymphocyte and monocyte populations were
unaﬀected, including the phagocytic activity of the monocytes
(Guilhem et al., 2013). Furthermore, TGFβ and endoglin have
been shown to be essential factors during inﬂammation and tis-
sue repair (Shull et al., 1992; Kulkarni et al., 1993; Larsson and
Goumans, 2001; Ishida et al., 2004; Doetschman et al., 2012).
As a consequence of these observations, HHT-1 and HHT-2
patients show an increased infection rate and leukopenia (Mathis
et al., 2012; Guilhem et al., 2013), revealing an important role for
disturbed inﬂammatory responses in HHT.
Since a role for ALK1 signaling in MNCs is less profound, we
will focus on the function of endoglin in inﬂammatory responses.
A role for endoglin in inﬂammatory disease became evident
when Torsney et al. (2002) studied the expression of endoglin
in human tissue samples and during wound healing. First, tis-
sue sections taken from various aﬀected organs (bowel, liver, and
skin) in diseases such as inﬂammatory bowel disease, liver cirrho-
sis and granuloma showed that endothelial endoglin expression
was highly upregulated, and correlated with inﬂammatory cell
inﬁltrate, including lymphocytes and macrophages, in the imme-
diate surrounding tissue (Torsney et al., 2002). Second, tissue
sections from, e.g., skin lesions showed that there was a strong
increase of endoglin 1–2 days after wounding, and a high level of
endoglin persisted for up to 1 month. Interestingly, the peak of
endothelial endoglin gene expression was reached at day 4, with
the subsequent peak of protein expression at day 7, which coin-
cides with the highest inﬂux of inﬂammatory cells during the ﬁrst
week after tissue injury, also known as the acute inﬂammatory
phase (Nahrendorf et al., 2007 and Figure 1).
In endoglin heterozygous mice, the restoration of a myocar-
dial infarction was disturbed compared to wild type mice. This
was characterized by a reduced cardiac function and by impaired
vascularization of the damaged tissue. Interestingly, injection of
human MNCs isolated from healthy volunteers into the circu-
lation of the mice after myocardial infarction improved cardiac
output and restored angiogenesis, while MNCs from HHT-1
patients did not have this eﬀect (van Laake et al., 2006). Further
analysis revealed that there were signiﬁcant lower numbers of
MNC of HHT-1 patients at the site of injury after myocardial
infarction when compared to control MNC (van Laake et al.,
2006; Post et al., 2010). In a similar study analyzing the kid-
neys, a reduced number of migrated MNC and macrophages was
observed in endoglin heterozygous mice (Docherty et al., 2006).
In conclusion, HHTpatients have altered subsets ofMNC and the
diﬀerential expression of endoglin can explain the disturbance in
their inﬂammatory response.
Recruitment of MNC: Homing
Mononuclear cell can either be recruited from diﬀerent sites,
such as the spleen, bone marrow or they are already resident
in tissue or in the blood. The process by which MNC, and
also stem cells, are attracted to sites of ischemia or inﬂamma-
tion is tightly regulated. The main cellular homing mechanism
is the SDF1-CXCR4 axis (Figure 2). MNC are retained in the
bone marrow and spleen due to the high SDF1 levels (Ceradini
et al., 2004). During ischemic disease, such as coronary artery,
cerebrovascular, or peripheral artery disease, levels of SDF1 are
increased. The occlusion of an artery results in hypoxia and
an increase in hypoxia inducible factor 1 alpha (HIF1α) levels.
HIF1α induces the expression of SDF1, which is then released
into the bloodstream creating a gradient of SDF1, causing HSC
and MNC to be recruited from the bone marrow and spleen,
and migrate toward the highest SDF1 concentration present in
the damaged tissue (Cencioni et al., 2012). A disturbed homing
balance may result in increased ﬁbrosis and adverse remod-
eling. For example, sustained activation of the SDF1-CXCR4
axis is observed in lung vessels of idiopathic pulmonary ﬁbrosis
patients (Smadja et al., 2014) and it was suggested that circu-
lating ﬁbrocytes contribute to intense remodeling of the pul-
monary vasculature. Furthermore, inﬁltration of leukocytes can
be mediated by integrins interacting and binding to endoglin,
which could well be diminished in HHT-1 patients (Rossi et al.,
2013).
Besides hypoxia, BMP9 is also a potent inducer of SDF1.
The eﬀects of BMP9 on SDF1 have been extensively studied
in endothelial cells. Surprisingly, knockdown of either endoglin
or ALK1 were shown to impair the upregulation of SDF1 by
BMP9 (Young et al., 2012). Mutations in BMP9 are thus likely
to decrease SDF1 levels, resulting in an impaired MNC homing
capacity. In conclusion, impaired homing of MNC and impaired
SDF1 regulation are a common feature of HHT.
In contrast, in other vascular diseases like atherosclerosis it
has been described that enhanced homing of MNCs is part
of the pathology. In atherosclerosis, low density lipoproteins
(LDLs) increase endothelial SDF1 levels at the distal ends of the
atherosclerotic plaques. In addition, LDL-induced SDF1 expres-
sion increase monocyte homing in vitro and monocyte adhesion
via ICAM-1 interaction to the endothelium was enhanced and
accelerated the progression of atherosclerotic plaque formation
(Wei et al., 2012).
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FIGURE 2 | Homing of MNC: the SDF1-CXCR4 axis. MNC circulate through the vasculature or are retained by high SDF1 in bone marrow and spleen. Upon
ischemia or tissue damage, SDF1 is released into the bloodstream creating an attracting gradient for MNC. The MNC home toward the damaged tissue via this
gradient. This process is negatively regulated by DPP4.
Therefore we conclude that homing via the SDF1-CXCR4 axis
is delicate and skewing of either one of the proteins or regulators
involved can cause defective inﬂammatory response and tissue
repair.
Regulation of MNC Recruitment by
DPP4
The recruitment of MNC to sites of tissue damage is tightly regu-
lated. In homeostasis, a negative regulator dipeptidyl peptidase 4
(DPP4) is able to prevent an uncontrollable inﬁltration of MNC.
DPP4, also known as CD26, is a 110 kd transmembrane pro-
tein expressed by many diﬀerent cell types, including endothelial
cells, epithelial cells, melanocytes, monocytes, and lymphocytes
(Yamada et al., 2009; Zhong et al., 2013). DPP4 is a peptidase
that will enzymatically remove aminoterminal dipeptides after
a proline or an alanine from speciﬁc proteins such as SDF1,
neuropeptide Y or glucagon-like-protein 1. DPP4 also has non-
enzymatic functions. It can inﬂuence T lymphocyte function by
binding to adenosine deaminase, and acts as a stimulatory fac-
tor in T lymphocyte activation pathways (Yamada et al., 2009).
Furthermore, DPP4 can interact and co-internalize with CXCR4
(Christopherson et al., 2002), again inhibiting the SDF1-CXCR4
axis.
The presence of DPP4 on the MNC cell membrane and tar-
get tissue, as well as the presence of the soluble form in plasma
will inﬂuence the migration and recruitment of MNC. How sol-
uble DPP4 is produced is not completely understood. One study
suggests that soluble DPP4 is formed by shedding DPP4 from the
cell membrane, while another study suggest that DPP4 is secreted
by either liver epithelium or lymphocytes (Cordero et al., 2009;
Wang et al., 2014b). The soluble form of DPP4 only lacks the
intracellular and transmembrane parts, but keeps its enzymatic
function (Lambeir et al., 2003).
Enhanced DPP4 activity will result in enhanced cleavage of
SDF1, resulting in loss of its chemotaxic function. The cleav-
age of SDF1 therefore eﬀectively puts a brake on the homing
signal (Christopherson et al., 2002). SDF1 has three isoforms,
SDF1α, β, and γ. While the functions of SDF1α and β are sim-
ilar (Shioda et al., 1998), SDF1γ has a higher aﬃnity for the
binding protein for chemokines, heparan sulfate (Rueda et al.,
2012). Heparan sulfate protects SDF1 against proteolysis induced
by DPP4, keeping the homing signal intact. SDF1γ was found
primarily expressed in the adult mouse heart and to a lesser
extent in the brain (Torres and Ramirez, 2009). However, this
restriction of organ expression in mice might not be similar
in humans or during disease as SDF1γ was found upregu-
lated in synovial dendritic cells and endothelial cells in patients
with rheumatoid arthritis (Santiago et al., 2012). The role of
SDF1γ in other diseases and the eﬀects of decreased sensitivity
to DPP4 are still unknown. However, increasing the expression
of SDF1γ may be an option to stimulate the homing process
in HHT-1 patients, making it a very interesting topic for future
research.
Alternative Homing Pathways and
Mechanisms
Although the SDF1-CXCR4 axis is the main pathway, there
are other mechanisms that inﬂuence the homing and the
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mobilization of MNC. For example, SDF1 is capable of bind-
ing to an alternative chemokine receptor, CXCR7. CXCR7
functions as a SDF1 receptor and increases MNC survival
and adhesion (Döring et al., 2014). Furthermore, CXCR4
is able to bind to macrophage migration inhibitory factor
(MIF). MIF is upregulated after MI, and speciﬁcally increases
monocyte homing by competing with SDF1 for binding to
CXCR4.
One other factor that inﬂuences homing is interferon-
inducible protein 10 (IP10 or CXCL10). This peptide is secreted
by a wide variety of cells, including MNC, ﬁbroblasts and
endothelial cells. IP10 functions as a lymphocyte chemotaxic
cytokine after binding to its receptor CXCR3. Besides stimulat-
ing homing, IP10 can also induce migration and proliferation
of endothelial cells and vascular smooth muscle cells (van den
Borne et al., 2014). The decreased numbers of lymphocytes
found in HHT patients (Guilhem et al., 2013) together with the
impaired resolution of inﬂammation (Peter et al., 2014), suggest
upregulation of IP10 might be another strategy to increase hom-
ing of MNC in HHT patients and restricting the inﬂammatory
response.
The sympathetic nervous system is another pathway involved
in the stimulation of homing and modulation of inﬂamma-
tory responses. Wang et al. (2014a) showed that after stroke,
β3-adrenergic receptor activity reduces the expression of SDF1
in the bone marrow, while the expression of CXCR4 was
increased in bone marrow cells. The activated β3-adrenergic
receptor also increased the levels of prostaglandin E2 in the
bone marrow, which in turn mediates T lymphocyte activation
via RANKL (Wang et al., 2014a). Moreover, cationic lipids such
as C3a, anaphylatoxin and cathelicidin increase cell responsive-
ness to low SDF1 gradients, so-called ‘priming’ (Ratajczak et al.,
2012).
In summary, the body has several mechanisms to respond
to stress signals, resulting in a rapid and increased mobilization
of MNC into the bloodstream followed by homing to the site
of injury. The SDF1-CXCR4 axis is the most prominent and is
malfunctioning in HHT-1 patients. Stimulating one of the other
pathways may correct the homing deﬁciency present in HHT
patients.
DPP4 Inhibition in Type II Diabetes
Mellitus and Cardiovascular Disease
Dipeptidyl peptidase 4 inhibitors like Sitagliptin, Vildagliptin,
and Saxagliptin are currently in use to treat patients with type 2
diabetesmellitus (T2DM). Already at baseline, serumDPP4 levels
are higher in T2DM patients compared to controls. DPP4 inhibi-
tion reduces the cleavage of glucagon-like-peptide 1, an incretin
protein that is released upon food intake to decrease insulin
levels (Mentlein et al., 1993; Deacon et al., 1998). Interestingly,
T2DM patients show a decrease in progenitor cell mobilization
(including EPC) from the bone marrow to the circulation – com-
parable to the impaired homing defect found in HHT. That
DPP4 inhibition is a feasible treatment modality for the improve-
ment of MNC homing is strengthened by the observation that
in DPP4 deﬁcient mice the mobilization capacity of the pro-
genitor cell population was restored after myocardial infarction,
and angiogenesis improved (Zaruba et al., 2009). Interestingly,
high serum DPP4 levels were found to be associated with the
occurrence of left ventricular dysfunction in T2DM patients
(Ravassa et al., 2013). Furthermore, DPP4 inhibition can aﬀect
cardiomyocyte metabolism by restoring their ability to switch
back to fatty acid metabolism during stress (Witteles et al.,
2012).
There are many more actions of DPP4 where inhibition
is capable of having protective eﬀects in cardiac ischemia-
reperfusion injury (Matheeussen et al., 2012). First, DPP4 is
able to cleave the vasoconstrictor neuropeptide Y, stimulating
angiogenesis via the eNOS pathway. Second, brain natriuretic
peptide (BNP) is associated with congestive heart failure and
is upregulated after ischemia (Mishra et al., 2014; Santaguida
et al., 2014). BNP is cleaved by DPP4, providing protective eﬀects
through decreased natriuresis and vasodilation (Vanderheyden
et al., 2009). Furthermore, DPP4 has a collagen binding domain –
and consequently decreases collagen and ﬁbronectin production,
and thereby has the potential to decrease ﬁbrosis (Thielitz et al.,
2007). Thus, inhibiting DPP4 has a beneﬁcial eﬀect on tissue
repair in more ways than only stimulating the SDF1-CXCR4 axis.
Dipeptidyl peptidase 4 inhibition using Sitagliptin has no
eﬀect on MNC subsets in healthy individuals (Price et al.,
2013), while in disease the eﬀects of DPP4 inhibition on MNC
migration are profound. In both wild type mice and mice
with induced continuously proliferating cardiomyocytes, com-
bining DPP4 inhibition with granulocyte colony-stimulating fac-
tor (G-CSF) increased stem cell mobilization and stimulated
myocardial repair (Zaruba et al., 2009, 2012; Theiss et al.,
2011, 2013), not only via increased retention in the ventricu-
lar wall, but also via reduction of the adverse remodeling and
enhanced angiogenesis. Patients who recover from a myocar-
dial infarction express high DPP4 levels on their MNCs, which
is associated with a decreased heart function (Post et al., 2012).
DPP4 inhibition is therefore also an interesting treatment option
for improving cardiac recovery. The ﬁrst meta analyses using
DPP4 inhibition in clinical trials show no adverse reactions
and even a reduction of cardiovascular risks in T2DM patients
treated with DPP4 inhibitors (such as Alogliptin, Vildagliptin,
Sitagliptin, Saxagliptin, or Linagliptin; Monami et al., 2013;
Avogaro et al., 2014). In contrast, DPP4 inhibition causes an
increased prothrombogenic status of endothelial cells and cor-
relates with upregulated tissue factor, the initiator of the coag-
ulation cascade (Krijnen et al., 2012). This implicates that care
should be taken, i.e., treatment may not always be beneﬁ-
cial to patients with increased coagulation status. Nonetheless,
the overall data implicate that DPP4 inhibition has posi-
tive eﬀects on tissue repair and subsequent cardiovascular
function.
DPP4 Inhibition in HHT
Interestingly, the expression of DPP4 is increased on MNCs
from HHT-1 patients and might explain the disturbed homing
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of MNC and impaired tissue repair (van Laake et al., 2006;
Post et al., 2010). In a follow up study the MNCs of HHT-1
patients were pretreated with a DPP4 inhibitor, which restored
the amount of cells present at the site of infarct (Post et al., 2010).
This study again suggests that not only the endothelial cells are
aﬀected in HHT-1, but also that the immune cells are involved.
How MNCs are speciﬁcally aﬀected by the disrupted TGFβ sig-
naling in HHT patients is still not clear. However, several studies
point toward a direct link between endoglin and the migratory
capacity and function of MNC (Torsney et al., 2002; Post et al.,
2010). In vitro studies also demonstrated a possible direct link
between TGFβ and DPP4. For example, the inhibition of DPP4
increases the expression of TGFβ in MNC (Reinhold et al., 1997;
Arndt et al., 2000), but induces a reduction of TGFβ expression
in skin ﬁbroblasts (Thielitz et al., 2007). In contrast, TGFβ is
able to downregulate DPP4 expression in MNC and to reduce
the numbers of DPP4+ cells. In HTT-1 patients this eﬀect was
less profound, but the DPP4 concentration on the cells is greatly
reduced (Post et al., 2010, 2012).
HowDPP4might interfere with TGFβ signaling and vice versa
is not clear. It was suggested that DPP4 has a co-receptor func-
tion with CD2 and CD3 on T lymphocytes, providing a possible
direct way of interacting with TGFβ/endoglin signaling on the
cell membrane (Morimoto and Schlossman, 1998; Gorrell et al.,
2001).
Clinical Perspectives and Conclusion
Hereditary hemorrhagic telangiectasia is not only a disease that
aﬀects the endothelial cells, the MNCs are also aﬀected. The
recruitment of MNC is impaired, due to increased levels of DPP4
and reduced levels of endothelial membrane endoglin. The inhi-
bition of DPP4 in other vascular diseases shows beneﬁcial results
not only on the homing toward damaged tissues, but also on
the recovery of functioning of the targeted tissue. For HHT, we
know that DPP4 inhibition improves the homing of MNC. Its
impact on actual tissue repair is unknown, and intriguing for
future research. DPP4 inhibition will potentially restore homing
and stimulate angiogenesis and tissue repair in HHT. However,
this only holds true when the function of MNC are not impaired,
e.g., improved homing of inﬂammatory macrophages will ham-
per the regenerative process. More knowledge on the homing
and functioning of MNC can therefore contribute to develop and
improve new therapeutic strategies for HHT.
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